R Is Hydrogen Or A Lower Saturated Alkyl Of Less Than Seven Carbons Patents (Class 514/629)
-
Publication number: 20110281945Abstract: To provide a drug, quasi-drug, food or drink that can act as a gastric acid secretion suppressant or a potassium channel inhibitor by including a composition that can be safely used and can be inexpensively produced. Each of these products contains one or more cooling sensation compositions that are compounds providing cooling sensation in an amount sufficient for exhibiting the efficacy thereof in a living body to which the product is administered.Type: ApplicationFiled: January 26, 2010Publication date: November 17, 2011Inventors: Yuichi Suzuki, Kenya Ishida, Mitsuhiko Fujiwhara
-
Publication number: 20110275720Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Inventor: Matthew W. Davis
-
Publication number: 20110268659Abstract: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.Type: ApplicationFiled: April 8, 2011Publication date: November 3, 2011Applicant: H R D CorporationInventors: Abbas HASSAN, Rayford G. ANTHONY, Aziz HASSAN
-
Patent number: 8048449Abstract: Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.Type: GrantFiled: August 30, 2006Date of Patent: November 1, 2011Assignee: Jubilant Organosys Ltd.Inventors: Namdev Kashid, Gour Mukherji
-
Publication number: 20110263716Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INCInventors: Matthew W. DAVIS, Shawn G. Watson, Hengsheng FENG
-
Publication number: 20110264043Abstract: A method of loading a drug library into an infusion pump includes transferring the drug library, stored on a remote device, to the infusion pump via a wireless connection. The drug library includes a plurality of subdirectories, and each subdirectory includes a care area, at least one drug, data associated with and dependent upon the drug(s), and at least one mode of operation for infusing the drug(s).Type: ApplicationFiled: October 22, 2009Publication date: October 27, 2011Applicant: CURLIN MEDICAL INC.Inventors: Paul T. Kotnik, Troy A. Bartz
-
Patent number: 8039515Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: GrantFiled: April 20, 2011Date of Patent: October 18, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 8039516Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: GrantFiled: May 18, 2011Date of Patent: October 18, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Publication number: 20110251166Abstract: The present invention provides a compound of formula (I) wherein: R1 is a group selected from —CH2OH, —NHC(O)H and R7 is a hydrogen atom; or R1 together with R2 form the group —NH—C(O)—CH?CH— wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon is atom in the phenyl ring holding R2; R3 is selected from hydrogen and halogen atoms or groups selected from —SO—R5, —SO2—R5, —NH—CO—NH2, —CO—NH2, hydantoino, C1-4alkyl, C1-4alkoxy and —SO2NR5R6; R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups; R5 is a C1-4alkyl group or C3-5 cycloalkyl; R6 is independently selected from hydrogen atoms and C1-4alkyl groups; n, p and q are independently 0, 1, 2, 3 or 4: m and s are independently 0, 1, 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13: the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.Type: ApplicationFiled: April 26, 2011Publication date: October 13, 2011Inventors: Carlos PUIG DURAN, Maria Isabel Crespo Crespo, Julio Cesar Castro Palomino Laria, Silvia Gual Roig, Eloisa Navarro Romero
-
Publication number: 20110245208Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.Type: ApplicationFiled: March 30, 2011Publication date: October 6, 2011Applicant: ALGYNOMICS INC.Inventors: Luda Diatchenko, William Maixner
-
Publication number: 20110237616Abstract: A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity.Type: ApplicationFiled: December 11, 2009Publication date: September 29, 2011Applicant: Novartis AGInventors: Timothy Dungan, Brian Warrington
-
Publication number: 20110230816Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: August 31, 2010Publication date: September 22, 2011Applicant: TYCO HEALTHCARE GROUP LPInventor: Warren Copp-Howland
-
Publication number: 20110218209Abstract: The present invention is a hypoallergenic nutrient delivery drug composition, that includes an active drug, a binder with non-genetically engineered and non-chemically treated starches and food powders, a filler with non-genetically engineered and non-chemically treated vegetable powder and/or extracts and a non-genetically engineered and non-chemically treated fruit powder and/or extract and a preservative that includes non-genetically engineered and non-chemically treated fruit juice, fruit oil and vitamins. There is also a sustained nutrient drug delivery composition that includes non-genetically engineered and non-chemically treated oils, starches and vegetable powders and/or extracts and fruit powder and/or extracts. There is also a broad spectrum nutrient delivery drug composition that includes non-genetically engineered and non-chemically treated pepper and oil mixtures or extracts.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventor: Paul Daniel Yered
-
Publication number: 20110217372Abstract: Provided is a fast dissolving oral tablet, and a method for the production thereof, including the steps of: compressing a mixture of active ingredients, pharmaceutically acceptable additives, and supercritical fluid-soluble substances to produce the tablets; and allowing the tablets to contact a supercritical fluid to extract supercritical fluid-soluble substances from fine pores in the tablets.Type: ApplicationFiled: November 9, 2009Publication date: September 8, 2011Applicant: CJ CHEILJEDANG CORPORATIONInventors: Si Beum Lee, Il Hwan Cho, Go Eun Lee, Tae Kun An, Il Ki Hong, Seon Oh Jeong, Yong Taek Lee, Kyung Min Shin, Myeong Sik Yoon
-
Publication number: 20110217248Abstract: Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Examplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, diproylene glycol, propylene glycol, ethanol, isopropanol, or a derivative therof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.Type: ApplicationFiled: November 11, 2010Publication date: September 8, 2011Applicant: ISW Group, Inc.Inventors: Monique Spann-Wade, Kenton N. Fedde
-
Publication number: 20110217374Abstract: Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 16, 2011Publication date: September 8, 2011Applicant: YUNGJIN PHARM. CO., LTD.Inventors: Dong-Joon OH, Byoung-Ki Kim, Byung-Kwan Moon, Ji-Seok Yoo, Dae-Hee Shin, Byung-Hwan Ryoo
-
Publication number: 20110213037Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: ApplicationFiled: May 18, 2011Publication date: September 1, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20110209227Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.Type: ApplicationFiled: February 4, 2011Publication date: August 25, 2011Inventors: Jeremy Kirk Nicholson, Elaine Holmes, John Christopher Lindon, Joanne Tracey Brindle, David John Grainger
-
Publication number: 20110207809Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.Type: ApplicationFiled: February 25, 2011Publication date: August 25, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Eric C. Carlson, Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni
-
Publication number: 20110207825Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: ApplicationFiled: May 17, 2011Publication date: August 25, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20110207824Abstract: A simplified paracetamol solution for an injectable and ready-to-use preparation is only composed of paracetamol, bi-distilled water and a buffer agent, the formulation having a maximal paracetamol concentration of 1 g/100 ml, a pH between 5.5 and 6.5 and an oxygen content inferior to 0.2 ppm. A method for preparing and packaging such a solution and a device for packaging such a solution are also disclosed.Type: ApplicationFiled: February 25, 2010Publication date: August 25, 2011Applicant: MOLY PHARMAInventor: Didier DOULEAU
-
Patent number: 8003617Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.Type: GrantFiled: November 9, 2005Date of Patent: August 23, 2011Assignee: Genzyme CorporationInventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
-
Patent number: 8003700Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulation prepared therefrom and uses thereof.Type: GrantFiled: April 2, 2009Date of Patent: August 23, 2011Assignee: Mutual Pharamaceutical Company, Inc.Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
-
Publication number: 20110195116Abstract: This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed.Type: ApplicationFiled: August 18, 2009Publication date: August 11, 2011Applicant: ADCOCK INGRAM HEALTHCARE PTY LIMITEDInventors: Kim Melissa Hobbs, Viness Pillay, Yahya Essop Choonara, Bradley Ryan Parsons
-
Publication number: 20110190397Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: ApplicationFiled: April 22, 2011Publication date: August 4, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20110190396Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: ApplicationFiled: April 20, 2011Publication date: August 4, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20110182986Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Applicant: TEMREL, INC.Inventors: Christopher J. Speirs, Peter Moir, Richard H. C. Williams, Michael S. Clark
-
Publication number: 20110182955Abstract: The invention relates to a hydrogel formed from water, at least one gel former, at least one pharmaceutical active ingredient or cosmetic ingredient and, optionally, further auxiliaries and additives obtainable by a) mixing water and optionally including auxiliaries and additives when appropriate, b) adding the gel former and homogenizing the mixture, c) adding the pharmaceutical active ingredient or cosmetic ingredient and, optionally, ionic compounds which induce gel formation, and homogenizing the mixture, d) pouring out the mixture onto a support and e) cooling the mixture to form the hydrogel, where steps a) to d) are carried out at a temperature between 79 and 95° C. This hydrogel is suitable for administering cosmetic ingredients onto or via the skin or mucous membrane of a human, in particular in the form of a cosmetic face pack.Type: ApplicationFiled: August 12, 2008Publication date: July 28, 2011Inventors: Michael Roreger, Iris Schnitzler, Christian Hausen
-
Publication number: 20110177168Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: ApplicationFiled: March 29, 2011Publication date: July 21, 2011Inventors: Shing Yue CHAN, Timothy James GRATTAN, Bounkhiene SENGMANEE
-
Publication number: 20110178180Abstract: Disclosed herein are deuterium-enriched colchicine, thiocolchicine, and derivatives thereof. The deuterium-enriched compounds are useful as, an antiproliferative agent, a muscle relaxant, an anti-inflammatory agent, or an anti-gout agent.Type: ApplicationFiled: January 17, 2011Publication date: July 21, 2011Inventors: Kurt Nielsen, Rajesh Manchanda
-
Patent number: 7981938Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: GrantFiled: January 14, 2010Date of Patent: July 19, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 7981930Abstract: Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.Type: GrantFiled: February 29, 2008Date of Patent: July 19, 2011Assignee: Adamas Pharmaceuticals, Inc.Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
-
Publication number: 20110171281Abstract: A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.Type: ApplicationFiled: January 14, 2010Publication date: July 14, 2011Inventor: Karl Wei Cao
-
Publication number: 20110159046Abstract: A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.Type: ApplicationFiled: June 22, 2010Publication date: June 30, 2011Inventor: Evangeline Cruz
-
Publication number: 20110159050Abstract: Disclosed is a process for modifying the morphology and/or polymorphism of an organic substance, which process comprises treating the solid substance, or a solution or dispersion thereof, with one or more amphiphilic proteins.Type: ApplicationFiled: June 23, 2009Publication date: June 30, 2011Applicant: BASF SEInventors: Andreas Hafner, Andreas Buthe, Paul Adriaan Van Der Schaaf, Franz Kaufmann, Gordon Bradley
-
Patent number: 7964647Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: GrantFiled: March 20, 2009Date of Patent: June 21, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 7964648Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: January 15, 2010Date of Patent: June 21, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 7964753Abstract: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Type: GrantFiled: June 7, 2010Date of Patent: June 21, 2011Assignee: Sunovion Pharmaceuticals Inc.Inventors: Gerald J. Tanoury, Chris H. Senanayake, Donald W. Kessler
-
Publication number: 20110142931Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders.Type: ApplicationFiled: February 18, 2011Publication date: June 16, 2011Inventors: Frank J. Bunick, Joseph Luber
-
Publication number: 20110136902Abstract: There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R1 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-14 arylcarbonyl group; R2 is a hydrogen atom or a C1-6 alkyl group; R3 is a hydrogen atom or a hydroxyl group; R4 is a hydrogen atom or a hydroxyl group; R5 is a hydrogen atom or a C1-6 alkyl group; R6 is a hydrogen atom or a hydroxyl group; and R7 is an acetyl group or the like.Type: ApplicationFiled: February 15, 2011Publication date: June 9, 2011Inventors: Masayuki MIYANO, Daisuke ITO, Norio MURAI
-
Publication number: 20110136851Abstract: The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH from about 2 to about 5. The invention is further directed to medicinal compositions comprising such a liquid excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liquid excipient bases.Type: ApplicationFiled: February 1, 2011Publication date: June 9, 2011Applicant: Wyeth LLCInventors: David Jaeger, Jay Dickerson, Annabelle Trimmer
-
Publication number: 20110130431Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.Type: ApplicationFiled: February 8, 2011Publication date: June 2, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Angela BERRY, Pier Francesco CIRILLO, Eugene Richard HICKEY, Doris RIETHER, David THOMSON, Renee M. ZINDELL, Nigel BLUMIRE, Chandana CHOWDHURY, Monika ERMANN, James Edward JENKINS, Innocent MUSHI, Christopher Francis PALMER, Malcolm TAYLOR
-
Publication number: 20110130289Abstract: Agrochemical compositions comprising (a) one or more branched alkyl polyglycosides, and (b) one or more biocides are disclosed. The compositions display improved solubility in water, and reduced foam generation.Type: ApplicationFiled: November 29, 2010Publication date: June 2, 2011Applicant: COGNIS IP MANAGEMENT GMBHInventors: Barbara Stefl, Jianhua Mao
-
Publication number: 20110129507Abstract: A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventor: Evangeline Cruz
-
Publication number: 20110123517Abstract: A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device.Type: ApplicationFiled: December 3, 2010Publication date: May 26, 2011Applicant: Medtronic, Inc.Inventors: Genevieve L. Gallagher, Kimberly Chaffin, Zhongping C. Yang
-
Publication number: 20110123652Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.Type: ApplicationFiled: October 6, 2010Publication date: May 26, 2011Inventors: Gunther Berndl, Jörg Breitenbach, Jörg Rosenberg, Robert Heger, Michael Stadler, Peter Wilke
-
Publication number: 20110117019Abstract: The present invention provides structured surfactant systems comprising water and from 0 to saturation of sugar, together with sufficient surfactant to form a structure capable of suspending solids, wherein the surfactant comprises a mixture of: (i) a major portion of at least one sugar ester and/or a triterpenoid glycoside (saponin) having an HLB greater than 10; and (ii) a minor portion of at least one fatty acid and/or lecithin. The invention further provides pharmaceutical compositions comprising a structured surfactant system of the invention and a pharmaceutical or veterinary active ingredient.Type: ApplicationFiled: February 6, 2009Publication date: May 19, 2011Inventor: John Hawkins
-
Publication number: 20110104272Abstract: Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: DEPOMED, INC.Inventor: Sui Yuen Eddie Hou
-
Publication number: 20110091531Abstract: A liquid cooling composition, which is a mixture of at least one primary cooling compound, at least one different secondary cooling compound and at least one ingestible non-polar solvent for the primary cooling compound, the weight ratios of primary cooling compound:secondary cooling compound:solvent being 1:1.5-2.25:2-4.4.Type: ApplicationFiled: May 19, 2009Publication date: April 21, 2011Applicant: GIV AUDAN SAInventors: Stefan Michael Furrer, Karen Ann Bell, Fabio Campanile, Aloysius Lambertus Doorn, Joshua Andrew Hagen
-
Publication number: 20110092447Abstract: Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of crucial genes which predispose a person with this condition to develop the disease phenotype. Thus, such compounds can be used for a suppressive therapeutic approach—the SUPPRESSION THERAPY—in order to inhibit or delay the onset or progression of the genetically predisposed disorder. Furthermore, a clinically used medicament can be manufactured for the SUPPRESSION THERAPY of such inherited predisposing conditions.Type: ApplicationFiled: December 22, 2010Publication date: April 21, 2011Inventors: Bernd Hentsch, Alexander B. Maurer, Sascha Hovelmann, Monika Raab, Elke Martin